Boston Scientific Is Down 60% From Its High. July 29 Is the Test.
The business kept growing. The stock did not follow.
The business kept growing. The stock did not follow.
NATO rearming and the Hormuz conflict just made defense the most visible trade in Q2.
Margins nearly doubled overnight. August 11 is when the math gets tested.
Auto onshoring, intermodal growth, and a ~9% revenue jump are all on the table.
A $2.2B FCF record and an EPS beat couldn't stop the selloff. Here is what actually matters now.
A $2 trillion quarter in rated issuance and an AI pivot that is already moving margins.
Value-added services up 25%+ and a $20B buyback. July 28 is the number that matters.
The FDA ruling changed what PM can legally say about ZYN. Q2 earnings this morning will show if the market…
Net earnings up 60% and guidance raised this morning. The stock is still down ~22% this year.
Rocket now services a $2.1 trillion mortgage portfolio spanning 9.4 million loans. The stock price does not reflect that yet.